NCT03564821 2025-11-04IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationMassachusetts General HospitalPhase 1 Completed18 enrolled